To clarify the roles of PD-L1 and PD-L2 as immune checkpoints in CRC, we assessed the effects of their respective inhibitors, along with a PD-1 inhibitor, on tumor growth in vivo. Here, PDCD1LG2 is linked to colorectal carcinoma.